Edition:
United States

AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

73.91USD
24 Jul 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$73.91
Open
--
Day's High
--
Day's Low
--
Volume
1,888
Avg. Vol
5,402,144
52-wk High
$75.04
52-wk Low
$55.06

Select another date:

Mon, Jul 24 2017

U.S. jury finds AbbVie liable for misrepresentation in AndroGel verdict

NEW YORK A federal jury in Chicago on Monday found AbbVie Inc fraudulently misrepresented the risks of its testosterone replacement drug AndroGel and ordered the drugmaker to pay $150 million in punitive damages.

U.S. jury finds AbbVie liable for misrepresentation in AndroGel verdict

NEW YORK A federal jury in Chicago on Monday found AbbVie Inc fraudulently misrepresented the risks of its testosterone replacement drug AndroGel and ordered the drugmaker to pay $150 million in punitive damages.

UPDATE 2-U.S. jury finds AbbVie liable for misrepresentation in AndroGel verdict

NEW YORK, July 24 A federal jury in Chicago on Monday found AbbVie Inc fraudulently misrepresented the risks of its testosterone replacement drug AndroGel and ordered the drugmaker to pay $150 million in punitive damages.

U.S. jury finds AbbVie liable for misrepresentation in first AndroGel verdict

NEW YORK, July 24 A federal jury in Chicago on Monday found AbbVie Inc fraudulently misrepresented the risks of its testosterone replacement drug AndroGel and ordered the drugmaker to pay $150 million in punitive damages.

AbbVie loses bid to overturn $15 million Depakote injury verdict

A federal judge has rejected AbbVie Inc's bid to overturn a $15 million verdict for a 10-year-old boy whose mother blamed his birth defect on its bipolar disorder drug Depakote, which she took while she was pregnant.

BRIEF-CytomX achieves development milestone in collaboration with AbbVie

* CytomX achieves development milestone in strategic oncology collaboration with AbbVie for CD71-targeting probody drug conjugate

BRIEF-EU medicines agency recommends approval of Aveo's kidney cancer drug

* EU Medicines Agency recommends approval of Merck KGAA multiple sclerosis drug

BRIEF-Enanta announces that AbbVie receives CHMP positive opinion for MAVIRET

* Enanta announces that abbvie receives chmp positive opinion for maviret™ (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis c in all major genotypes (gt1-6)

BRIEF-EMA recommends approval of Merck's multiple sclerosis drug

* EU Medicines Agency recommends approval of Merck KGAA multiple sclerosis drug

BRIEF-AbbVie sets quarterly cash dividend of $0.64 per share

* Abbvie Inc says declared a quarterly cash dividend of $0.64 per share Source text for Eikon: Further company coverage:

Select another date: